Search the web
Sign In
New User? Sign Up
PozHealth
? Already a member? Sign in to Yahoo!

Yahoo! Groups Tips

Did you know...
Want your group to be featured on the Yahoo! Groups website? Add a group photo to Flickr.

Best of Y! Groups

   Check them out and nominate your group.
Having problems with message search? Fill out this form to ensure your group is one of the first to be migrated to the new message search system.

Messages

  Messages Help
Advanced
Messages 22960 - 22990 of 31322   Newest  |  < Newer  |  Older >  |  Oldest
Messages: Show Message Summaries   (Group by Topic) Sort by Date v  
#22990 From: Travis32824 <travis32824@...>
Date: Mon Oct 1, 2007 4:06 am
Subject: Re: kaposi return
travis32824
Offline Offline
Send Email Send Email
 
Still taking chemo for mine, but went onto Valtrex for mild shingles. Shingles went away almost immediately, but oddly, the KS seems to be responding too. I think that it may have to do with the fact that KS is due to a herpes virus, who knows. This round of shingles was nowhere near as bad as my first round years ago. This time I knew what to look for, so I went to my ARNP right away, no hesitation.
Thankfully, KS is treatable, even with long sessions of chemo. As long as its not on a vital organ, it's not life threatening. (just unappealing to look at sometimes)
Travis

Joe Fiore <joe_d_o@...>
wrote:

as an addendum to the mention of KS return.
 
it appears to be mild cases and easily treatable, as well as still rare.
 
read more:
 
http://12.42.224.225/healthnews/healthday/070926HD608579.htm
 
Joe


Connect to the next generation of MSN Messenger  Get it now!



 SEIZE THE DAY! ENJOY TODAY, SMELL THE ROSES AND HUG YOURSELF


Moody friends. Drama queens. Your life? Nope! - their life, your story.
Play Sims Stories at Yahoo! Games.

#22989 From: Joe Fiore <joe_d_o@...>
Date: Mon Oct 1, 2007 1:52 am
Subject: kaposi return
joe_d_o2000
Offline Offline
Send Email Send Email
 

as an addendum to the mention of KS return.
 
it appears to be mild cases and easily treatable, as well as still rare.
 
read more:
 
http://12.42.224.225/healthnews/healthday/070926HD608579.htm
 
Joe


Connect to the next generation of MSN Messenger  Get it now!

#22988 From: "openwider_sd" <health1@...>
Date: Sun Sep 30, 2007 9:40 pm
Subject: Experiences with Buttock reconstruction with PMMA
openwider_sd
Offline Offline
Send Email Send Email
 
I have had PMMA used to correct facial lipoatrophy.  I have had no
hardening or other negative sensations from the treatments, and the
injections were done over 3 years ago.

My partner is considering having PMMA used for some minor buttock
restoration.  His primary concern is the possibility of the treated
area becoming unnaturally "hard" to the touch due to the concentration
of the material used.

I would appreciate hearing from anyone who has had buttock restoration
using PMMA and their experiences.  Particularly has anyone experienced
the treated area becoming hardened sometime years or more in the future?

Thanks for your feedback in advance.

Tom

#22987 From: Mitchell Lucio <mitch4homes@...>
Date: Sun Sep 30, 2007 2:34 pm
Subject: Re: lipoadtrophy and social isolation
pozinkensington
Offline Offline
Send Email Send Email
 
Wow Butch....Thanks!  Couldn't agree more with your response.  At 43 what has helped me almost on a daily basis when faced with negative thoughts about my lypodistrophy. (21 1/2 neck size) is to be grateful that I am still alive and to love myself first.  With this confidence knowing that I am a loving, handsome and loved person it carries me through each day.  Although I am the one always thinking people are looking at me funny it almost always ends up being that they are looking at something else.  I have often been told by people that I address my self consciousness about my fat to that they didn't notice that first.  They noticed how stong I carry myself and my smile.
 
Keep smiling and love yourself!
 
Mitch

#22986 From: Butch <longjohnmaniac@...>
Date: Sun Sep 30, 2007 5:45 pm
Subject: Re: Bones Breaking
longjohnmaniac
Offline Offline
Send Email Send Email
 
About the testosterone, hypogonadism is indeed a major risk factor for osteoporosis in men.  Saying you're in the "normal" range doesn't mean much.  The normal range for T is huge.  Unless you know your baseline level when you were young and presumably at your peak, it's hard to say how much of a decline you've had.   Are you having any other signs of hypogonadism (low libido etc)?   Do you know your numbers and your lab's reference range?  What is the level of your free and bioavailable testosterone?  Total testosterone is almost meaningless.   Did your doctor check for sex hormone binding globulin?  If she hasn't checked for free T, she probably isn't up to speed on testosterone.   You should request copies of your labs so you can see for yourself.  You're entitled to a copy of your labs.
Check out this article (partially quoted below)

http://courses.washington.edu/bonephys/opmale.html
"Hypogonadism is an important cause of osteoporosis in men. The recent MrOS study found that men whose serum bioavailable testosterone was in the lowest quartile had a 2.5 times increased risk of non-spine fractures compared with the highest quiartile. Bioavailable estrogen also was related to fractures. Interestingly, the estrogen was related to bone density, so the fracture effect was not seen after adjustment for bone density. The testosterone risk was independent of bone density - in fact, it was not even correlated to bone density. Other studies, however, have found a relationship between testosterone levels and bone density.

Also men clinically diagnosed with hypogonadism consistently have low bone density. Measurements of testosterone in men with hip fractures show low levels of free testosterone. Bone biopsies from hypogonadal men with osteoporosis show a high bone turnover rate, as compared with eugonadal osteoporotic men. In men with Klinefelter's syndrome, those who were treated with testosterone at an early age showed better bone density than those treated when they were older. Men with hyperprolactinemia who were treated showed improvements in the bone density only if the testosterone levels increased.
It is interesting to note that estrogen is necessary for bone strength in men. This has been clearly demonstrated in men who lack aromatase, the enzyme which converts testosterone into estrogen. These men fail to close their epipheses and grow tall, but the bone density is low. Treatment with estrogen reverses the abnormalities."


Luggage? GPS? Comic books?
Check out fitting gifts for grads at Yahoo! Search.

#22985 From: PoWeRTX@...
Date: Sun Sep 30, 2007 12:26 pm
Subject: Herpes Suppression: It All Seemed So Simple
nelsonvergel
Offline Offline
Send Email Send Email
 
 
I am 100 % convinced that treating HSV can help control HIV viral load. I have been taking Famvir for 8 months now and my VL has been the lowest and most stable ever, even after going up due to raltegravir resistance.  I used to have constant hairy leukoplakia, blisters in my lips on side my mouth, and had shingles twice. Actually, the week i broke through raltegravir I was having problems with shingles.
 
I think anyone who experiences herpes outbreaks (sexual or not) should be on prophylaxis to also prevent HIV VL blips and breakthroughs.
 
 
 
Herpes Suppression: It All Seemed So Simple

September 2007

The connection between chronic genital herpes (HSV-2) and HIV risk has grown ever stronger. A 2006 meta-analysis of previous studies noted that preexisting HSV-2 infection tripled the risk of acquiring HIV in men and women generally (Freeman et al. AIDS 2006). (For gay men, the added risk seemed somewhat lower, while studies in female sex workers were ambiguous.) A new study (Brown et al. AIDS 2007) published at the time of the conferences calculated that 42% of the HIV contracted by Ugandan women and 65% of that contracted by Zimbabwean women could have been avoided in the absence of HSV-2.

There is a strong biological rationale that genital ulcers open a portal through the protective outer mucosal layers, These inflammatory zones, in addition, contain a concentration of the types of immune cells infected by HIV (see, for example, Donaghy et al. IAS 2007 abstract MOPEA091). The reverse is also quite likely true: genital herpes coinfection can increase infectiousness of persons who already have HIV. University of Washington researchers reported two years ago that genital tract HIV levels increased during periods of HSV-2 reactivation and were related to the quantity of herpes virus present (Baeten et al. JID 2005). At ISSTDR, the same group reported on the effect of the anti-herpes drug valacyclovir on 20 otherwise untreated Peruvian HIV positive women. Both plasma and cervical HIV levels were moderately lower than in women taking placebo, by 45% and 56%, respectively (Baeten et al. ISSTDR 2007 abstract O-096). A study of 136 HIV positive Burkina Faso women published similar results earlier this year (Nagot et al. NEJM 2007).

At ISSTDR, the HIM (Health in Men) gay male cohort from Sydney led off the conference with unsettling findings (Fengyi et al. ISSTDR 2007 abstract O-001). HIM observed a significant association between HSV-1 and HIV infection, but not between HSV-2 and HIV. HSV-1 generally causes cold sores and can also infect the genital and anal regions. HSV-1 infection is often associated with oral sex. In contrast with HSV-2, anogenital HSV-1 is usually self-limiting. Nonetheless, its role in genital ulcer disease is thought to be growing, especially in such populations as MSM and college students (Xu et al. JAMA 2006; Lafferty et al. JID 2000; Roberts et al. Sex Trans Dis 2003)

Stained Biopsies of Normal Skin (left) and Herpes Lesion (Right)


The herpes lesion biopsy shows a loss of the outer skin layer and invasion by immune cells.
Source: Zhu, J. et al. J. Exp. Med. 2007;204:595-603

The accumulation of STDs in high-risk populations may confuse the observed associations. Still, the HIM results imply that you have to test for and treat HSV-1 as well as HSV-2 (not to mention other STDs) to have an effect on HIV transmission. Fortunately, the same drugs attack both types of herpes. The big surprise this summer emerged from the initial large studies of herpes suppression, in both HIV positive and HIV negative women from northern Tanzania. Both studies involved acyclovir, an older, much cheaper version of valacyclovir. The HIV negative study is the first to test whether a continuous anti-herpes regimen would reduce the likelihood of contracting HIV in people already infected with genital herpes (Watson-Jones et al. ISSTDR 2007 abstract O-100). The answer from this study was no: among the 821 women enrolled, the rate of contracting HIV was practically the same whether they received acyclovir (400 mg twice a day) or placebo (above 4 per 100 person-years).

Only about half the trial participants faithfully took their assigned medication, however. When considering just those who took more than 90% of their pills, the acyclovir recipients had a markedly lower HIV incidence rate compared to the women on placebo, 2.5 versus 4.3 per 100 person-years. But there weren't enough HIV cases within this subpopulation to make the results statistically significant.

Even more surprising were the findings from the accompanying cohort of 383 HIV+/HSV-2+ coinfected women (Tanton et al. ISSTDR 2007 abstract O-99). Here, daily acyclovir showed no significant benefit over placebo in reducing levels of either genital HIV or genital HSV-2. Again, only about half the cohort took more than 90% of their assigned pills. It would seem that a more potent herpes medication is called for. (The HSV-2 results were not reported for the HIV negative trial.) Certainly, better adherence to the medication schedule is necessary.

The need for successful, continual HSV-2 suppression to protect against HIV transmission was stressed by another report at ISSTDR (Mark et al. ISSTDR 2007 abstract O-30). Twenty-five HSV-2+ adults had their genital secretions checked four times a day for 60 days. HSV-2 was detectable on 20% of the days, representing 1.5 reactivations per month. More than half of these reactivations were asymptomatic and lasted less than 12 hours

The United States National Institutes of Health, meanwhile, is sponsoring a much larger multinational trial (in the U.S., Peru and southern Africa) comparing acyclovir with placebo in nearly 3,000 HIV-, HSV-2+ women and gay men. The trial's main goal is to see whether acyclovir reduces HIV acquisition, but it will also check on medication adherence and HSV-2 suppression. The chances of statistically significant results are enhanced by the larger trial population, which greatly helps to break down the results by adherence. There's a chance that the trial will confirm that acyclovir is not the right drug for this task. The results will not be available for another two to three years.

Summary of HIV Prevention Trial Results

Trial New HIV infection ratio
(95% confidence interval)*, intervention vs. placebo
HSV-2 suppression, daily acyclovir vs. placebo 1.12 (0.7-1.9)
HSV-2 suppression, participants with 90+% adherence 0.58 (0.3-1.4)
Diaphragm plus condoms vs. condoms alone 1.05 (0.84-1.32)
Diaphragm vs. condoms, no condom use in the 3 months prior to study entry 0.74 (0.46-1.19)
Microbicide, cellulose sulfate vs. placebo gel (CONRAD) 2.17 (1.06-4.45)
Microbicide, cellulose sulfate vs. placebo gel (FHI) 0.9 (0.3-2.5)
*The 95% confidence ratio (95% CI) is in parentheses. The infection ratio indicates the extent to which the trials' active agents block (rate ratio less than 1.0) or promote (rate ratio above 1.0) HIV transmission. The 95% CI is the range within which the ratios are likely to occur 95% of the time, due to the impact of chance fluctuations. If that range crosses 1.0, then the result is not considered statistically significant. The greater number of people in a trial, the narrower the 95% CI, and the more trustworthy the observed results.

Back to September 2007 issue of HHS Watch


Regards,

Nelson Vergel
powerusa dot org




See what's new at AOL.com and Make AOL Your Homepage.

#22984 From: Nelson Vergel <nelsonvergel@...>
Date: Sat Sep 29, 2007 10:24 pm
Subject: Vitamin E Trials 'Fatally Flawed'
nelsonvergel
Offline Offline
Send Email Send Email
 
Vitamin E Trials 'Fatally Flawed'




   Science Daily —
Generations of studies on vitamin E may be largely meaningless,
scientists say, because new research has demonstrated that the levels
of this micronutrient necessary to reduce oxidative stress are far
higher than those that have been commonly used in clinical trials.







   In a new study and commentary in Free Radical
Biology and Medicine, researchers concluded that the levels of vitamin
E necessary to reduce oxidative stress -- as measured by accepted
biomarkers of lipid peroxidation -- are about 1,600 to 3,200 I.U.
daily, or four to eight times higher than those used in almost all past
clinical trials.
This could help explain the inconsistent results
of many vitamin E trials for its value in preventing or treating
cardiovascular disease, said Balz Frei, professor and director of the
Linus Pauling Institute at Oregon State University, and co-author of
the new commentary along with Jeffrey Blumberg, at the Jean Mayer USDA
Human Nutrition Research Center on Aging at Tufts University.
"The
methodology used in almost all past clinical trials of vitamin E has
been fatally flawed," said Frei, one of the world's leading experts on
antioxidants and disease. "These trials supposedly addressed the
hypothesis that reducing oxidative stress could reduce cardiovascular
disease. But oxidative stress was never measured in these trials, and
therefore we don't know whether it was actually reduced or not. The
hypothesis was never really tested."
The level of vitamin E that
clearly can be shown to reduce oxidative stress, new research is
showing, is far higher than the level that could be obtained in any
diet, and is also above the "tolerable upper intake level" outlined by
the Institute of Medicine, which is 1,000 I.U. a day. OSU researchers
are not yet recommending that people should routinely take such high
levels, but they do say that controlled clinical trials studying this
issue should be aware of the latest findings and seriously consider
using much higher vitamin E supplement levels in their studies.
In
lab, animal or human studies, there's evidence that vitamin E can
reduce oxidative stress, inhibit formation of atherosclerotic lesions,
slow aortic thickening, lower inflammation, and reduce platelet
adhesion. Some human studies using lower levels of vitamin E
supplements, such as 100 to 400 I.U. a day, have shown benefits in
reducing cardiovascular disease risk, and others have not. An
underlying assumption was that these levels were more than adequate to
reduce oxidative stress, since they far exceeded the "recommended
dietary allowance" or RDA for the vitamin, a level adequate to prevent
deficiency disease.
"What's now clear is that the amount of
vitamin E than can conclusively be shown to reduce oxidative stress is
higher than we realized," Frei said. "And almost none of the studies
done with vitamin E actually measured the beginning level or reduction
of oxidative stress."
Proper studies of vitamin E, researchers
say, must be done carefully and take into account the newest findings
about this micronutrient. It's now known that natural forms of the
vitamin are far more readily absorbed than synthetic types. It's also
been discovered that supplements taken without a fat-containing meal
are largely useless, because in the absence of dietary fat vitamin E is
not absorbed.
Some clinical trials may wish to study the long
term effect of vitamins on healthy individuals. But if a clinical trial
seeks to learn the value of reducing oxidative stress, they should
select patients in advance for those who have high, measurable
oxidative stress -- often people who are older or have a range of heart
disease risk factors, such as obesity, poor diet, hypertension or other
problems. Cognizance should also be taken of people with health issues
that may further increase their vitamin needs, such as smokers.
"A
pill count simply isn't enough to determine the value of vitamin E,"
Frei said. "We need to select people for trials properly, make sure
they are taking the right form of the vitamin, at the right levels and
at the right time, and then verify the metabolic results with
laboratory testing."
"Only when we do these studies right will we
answer questions about the value of vitamin E in addressing
cardiovascular disease," he said. "So far we've been flying blind."
A
parallel, Frei said, would be presuming to test the value of a statin
drug, which lowers cholesterol, without ever measuring cholesterol
levels in the test subjects, neither at the beginning nor at the end of
the study. Such trials would be ridiculed in the science community.
So far, that's the way vitamin E has been studied.
The
use and intake of vitamins, experts say, has traditionally been thought
of in terms of overt deficiency -- for example, not enough vitamin C
causes scurvy. Much less research has been done on the levels that can
help create optimum health. The issue is of special importance with
modern populations that have very different diets, activity levels and
increased lifespan, and are dying from much different causes --
predominantly heart disease and cancer -- than people of past
generations.


   Note: This story has been adapted from material provided by Oregon State
University.













Regards,
Nelson Vergel
powerusa dot org

#22983 From: Nelson Vergel <nelsonvergel@...>
Date: Sat Sep 29, 2007 10:23 pm
Subject: acetyl-l-carnitine and alpha lipoic acid and cognitive decline
nelsonvergel
Offline Offline
Send Email Send Email
 
You Can Teach An Old Dog New Tricks -- With The Right Diet




   Science Daily —
These supplements, acetyl-l-carnitine and alpha lipoic acid, are
continuing to be studied in work with humans, and scientists believe
they may provide a new approach to the neurodegeneration and cognitive
decline common with aging.



Supplements
of two antioxidant compounds -- acetyl-l-carnitine and alpha lipoic
acid -- have been found to significantly increase the ability of
"geriatric" beagle dogs to learn a new task. (Credit:
iStockphoto/Joshua Blake)




   The newest study was just
published in FASEB Journal, produced by the Federation of American
Societies for Experimental Biology, by researchers from the Linus
Pauling Institute at Oregon State University, the University of
Toronto, University of California/Berkeley, Children’s Hospital Oakland
Research Institute, and Juvenon, Inc.
It found that supplements
of these two antioxidant compounds, which are believed to play a role
in slowing mitochondrial decay in the cell, significantly increased the
ability of “geriatric” beagle dogs to learn a new task.
The study
builds on similar findings made several years ago, done with mice and
published in Proceedings of the National Academy of Sciences. In that
research, the activity and energy level of old rats taking these same
supplements almost doubled, and memory and cognitive function improved.
“The
prospects for cognitive improvement from use of these supplements is
both fascinating and exciting,” said Tory Hagen, an associate professor
in OSU’s Linus Pauling Institute, and recognized expert on the
biological processes of aging.
“This is the first time these two
compounds, by themselves, have been tested in canines, which have
brains that are more biologically similar to humans than some other
animal models,” Hagen said. “The results should be relevant to what we
could expect with humans, and are very encouraging.”
In this
study, an inbred line of older, very similar beagle dogs were taught
how to find a food treat by identifying certain markers, such as a
yellow wooden peg. Applied scents were used to control for any tip-off
by sense of smell. Some dogs received short-term dietary
supplementation with acetyl-l-carnitine and lipoic acid, and others did
not.
On one task, four of six dogs receiving supplements quickly
learned to find the food treat by identifying the correct marker, while
only two of six dogs on normal diet succeeded. After 15 more weeks of
training, more than 80 percent of supplemented dogs were successful,
while only 50 percent of those not receiving supplements could learn
the new task.
“We’ve shown in some previous animal work that
these supplements could improve memory and energy level,” Hagen said.
“Now we’re seeing that animals receiving supplements are much more
readily able to learn new things as well, even at an advanced age.”
In
these tests, the effects of supplementation with these compounds
appeared to work fairly quickly, in a matter of days or weeks, the
scientists said. Some other studies, however, have required much longer
periods of supplementation for various antioxidants to improve
cognitive performance.
Humans also experience loss of the type of
object and spatial discrimination that was improved by supplements in
these animal tests – it’s often one of the early signs of human
dementia.
The scientists suggested in the paper that long-term
supplementation “may be effective in attenuating age-associated
cognitive decline by slowing the rate of mitochondrial decay and
cellular aging.” Enhancing the function of mitochondria - which provide
almost all of a cell’s energy - could literally be providing animals
with more “mental energy,” leading to improved memory and learning, the
study indicated. The compounds may also cause increased synthesis of a
neurotransmitter called acetylcholine.
An increasing body of
research suggests that mitochondria may be an “Achilles heel” for
absorbing age-related damage, as part of the natural process of
oxidation in the body and the related “free radicals” that are produced
and can cause cellular damage. As the power plant of cells,
mitochondria perform many of the roles critical to cell function, use
up to 90 percent of the oxygen humans breathe, but are also among the
first cellular components to be damaged by reactive radical oxygen
species.
This study was funded by private industry, including companies that produce the
compounds being studied.
Clinical experiments with humans using these supplements are already under way,
scientists said.


   Note: This story has been adapted from material provided by Oregon State
University.

Regards,
Nelson Vergel
powerusa dot org

#22982 From: "Gary" <Gary85710@...>
Date: Sun Sep 30, 2007 1:56 pm
Subject: Chantix
gary85741
Offline Offline
Send Email Send Email
 

     I see that last year a few studies were posted regarding the efficacy of Chantix as a smoking cessation medication.

     Well...it works.  I smoked two packs a day for years.  I loved smoking.  Recently however a health issue arose which clearly dictated that I must stop.  I went on Chantix Sept. 20.  For the first week it is okay to still smoke...I averaged five cigarettes a day during that time (a 88% decrease.)  On day eight, one is supposed to stop.  This is my fourth smoke-free day.  The cravings at worst have only been moderate, and that's been transitory.  Yesterday was easier.

     Chantix is a great medication.  It works by blocking the nicotine receptors in the brain.  Downside is that it costs $100/mo. and is customarily taken for three months.  It wasn't on my HMO drug formulary.

     You do have to want to quit.  No drug will create the motivation.  But a potentially serious smoking-related health issue sure the heck will!

    If you want to quit, please give Chantix a try.  (As an aside...unlike some former smokers, I will never belittle or criticize smokers.)

Gary


#22981 From: "Richard Kearns" <rk@...>
Date: Sat Sep 29, 2007 10:14 pm
Subject: RE: Dronabinol and marijuana provide similar benefits to HIV-infected patients
captnsaintlu...
Offline Offline
Send Email Send Email
 

n---

 

abrams/jaids study: smoked cannabis works better in HIVers than marinol (699)

http://aids-write.org/?p=613

Investigators said that the administration of oral THC produced similar weight gains in patients, but only at doses that were “eight times current recommendations.” The US Food and Drug Administration approved the prescription use of Marinol (a gelatin capsule containing synthetic THC in sesame oil) to treat HIV/AIDS-related cachexia in 1992.

 

namasté

 

---lyr


From: PozHealth@yahoogroups.com [mailto:PozHealth@yahoogroups.com] On Behalf Of PoWeRTX@...
Sent: Saturday, September 29, 2007 1:26 PM
To: pozhealth@yahoogroups.com
Subject: [PozHealth] Dronabinol and marijuana provide similar benefits to HIV-infected patients

 

  Dronabinol and marijuana provide similar benefits to HIV-infected patients
Wednesday, September 26, 2007
http://www.eatg.org/news/newsitem.php?id=3442
  
    Dronabinol and marijuana provide comparable benefits to HIV-infected patients who already smoke marijuana.

 


Regards,

Nelson Vergel
powerusa dot org




No virus found in this incoming message.
Checked by AVG Free Edition.
Version: 7.5.488 / Virus Database: 269.13.33/1037 - Release Date: 09/29/2007 1:32 PM


No virus found in this outgoing message.
Checked by AVG Free Edition.
Version: 7.5.488 / Virus Database: 269.13.33/1037 - Release Date: 09/29/2007 1:32 PM


#22980 From: PoWeRTX@...
Date: Sat Sep 29, 2007 4:26 pm
Subject: Dronabinol and marijuana provide similar benefits to HIV-infected patients
nelsonvergel
Offline Offline
Send Email Send Email
 
  Dronabinol and marijuana provide similar benefits to HIV-infected patients
Wednesday, September 26, 2007
http://www.eatg.org/news/newsitem.php?id=3442
  
    Dronabinol and marijuana provide comparable benefits to HIV-infected patients who already smoke marijuana.
 

Regards,

Nelson Vergel
powerusa dot org




See what's new at AOL.com and Make AOL Your Homepage.

#22978 From: Elias Sanchez <vaeagle2@...>
Date: Sat Sep 29, 2007 3:31 pm
Subject: High-carb diet may help you think faster
eesdc_2001
Offline Offline
Send Email Send Email
 
 High-carb diet may help you think faster

By Joene Hendry Fri Sep 28, 4:49 PM ET

NEW YORK (Reuters Health) - A low-carbohydrate/high-fat diet and a high-carbohydrate/low-fat diet both improve weight loss, enhance mood, and speed thinking, a study shows, but the low-carb diet may offer less benefit in terms of the rate of cognitive processing.
ADVERTISEMENT

"In overweight and obese patients, following an energy-restricted dietary plan for weight loss is associated with improvements in mood, regardless of macronutrient composition," Dr. Grant D. Brinkworth told Reuters Health.

Moreover, while both a high- and low-carbohydrate diets seem to boost the speed of cognitive processing, "the interesting result was that compared to the high-carbohydrate diet, subjects consuming the low-carbohydrate diet had a smaller improvement," Brinkworth noted.

Brinkworth, of the Commonwealth Scientific and Industrial Research Organization-Human Nutrition, in Adelaide, Australia and colleagues compared mood and cognitive function in overweight or obese, but otherwise healthy, men and women who were between 24 to 64 years old.

Over 8 weeks, participants followed one of two diets of similar caloric and macronutrient content, the researchers report in the American Journal of Clinical Nutrition.

The low-carbohydrate diet contained 35 percent total protein, 61 percent total fat (20 percent saturated fat) and 4 percent total carbohydrate. The high-carbohydrate diet consisted of 24 percent total protein, 30 percent total fat (less than 8 percent from saturated fat), and 46 percent total carbohydrate.

The researchers found no changes in mood among the 93 participants consuming either the low- or high-carbohydrate diet for the study duration. They did find, however, a small between-group difference, favoring the high-carb dieters, in the speed in which participants performed intelligence and reasoning tests.

The findings suggest, Brinkworth noted, that "very low carbohydrate diets may offer less benefit than a high carbohydrate diet for improving cognitive function."

The investigators say further research is needed to determine whether similar outcomes occur with similar diets of longer duration.

SOURCE: The American Journal of Clinical Nutrition, September 2007.


#22977 From: Butch <longjohnmaniac@...>
Date: Sat Sep 29, 2007 2:07 pm
Subject: Re: lipoadtrophy and social isolation
longjohnmaniac
Offline Offline
Send Email Send Email
 
Not that you probably haven't already realized this yourself, but your "hot" friend sounds like he is either a rather shallow person, or perhaps just didn't relate to you on a deeper level.  Always better to find these things out earlier rather than later.  I can understand wanting to find a physical "specimen" to fulfill personal fantasies, since I've looked for them all my life (and unashamedly still do), so I wouldn't condemn him for his behavior.   His deception may have been his crude way of trying not to hurt your feelings because he didn't know how to talk to you honestly.   But if you're seeking a soul-mate, good friend, or life partner, physical attributes should soon become very secondary and in fact, almost irrelevant.  I have met far too many people of both sexes who were astoundingly handsome/beautiful but who had little to offer (as far as I could tell) in terms of personality and depth.  Some of the most beautiful and smartest people I've known have been those with major "physical defects".   I think those of us who are still in our 20's, 30s and even 40s find the devastation of physical deformity of any kind particularly hard to deal with since we're still driven so much by biological impulses which stem from natural selection and "survival of the fittest". When I lost one of my testicles to cancer at age 33, I cried for days until the HMO promised me a prosthesis so I would look normal again.  So I certainly have total understanding for those wanting to mitigate the effects of lipodystrophy, which is far more visible than a missing nut.      But if it's any consolation, as you get older it becomes  less of an issue, especially since so many people just become far less stunning as they age.   At my point in life (55),  I still want to look good, but I wouldn't bet a relationship on physical appearance alone.   I"d rather be with somebody who will bring me chicken soup when I'm not feeling well,  hug me when I'm down and astound me with their metaphysical insights.   I agree with you that support, whether it's a support group, or just a good friend, is the best way to deal with what you're feeling right now.   I hope you find someone who has deeper feelings for you and will stay with you even if you lost your legs, had a jaw removed, or turned bald.
Butch
Lipoatrophy and social isolation...
Posted by: "RW736@..." RW736@...
Date: Fri Sep 28, 2007 6:57 am ((PDT))

Pozgroup members:


This recent thread concerning lipoatrophy and social interaction
caught my
attention. I recently dated a really nice guy whom liked me from day
one. We
dated for a couple of months before he stopped being intimate with me.
This is
something I was not used to at all, being a sexual person. He is very
hot and
it was hard not to wanna rape him! However, he said he just wasn't
interested
in intimacy -- period. Well, then I caught him cruisin the Internet for
sex
-- right after being rejected by him. This happened twice (I took him
back,
like an idiot). He is newly on Meds, a big guy, and not suffered any
wasting. I
however, have substantial lower body wasting. It turned him off and
hurt me
horribly in the process. After a year and a half of waiting this out, I
dumped
him. I still have issues about it and feel like crawling under a rock.
With
gayland and society as a rule so dependent on looks, lipo is a horrible
affliction
to suffer. After surviving so long (most lipo sufferers are long term
survivors), and suffering so much with treatment, opportunistics, and
watching all
your friends die -- now this!
This is a horrible affliction to deal with, Lipodystrophy is a real
and
dangerous side effect of long term treatment and survival with HIV. It
took the
medical community way too long to take it seriously - which I believe
was
prejudice rooted. It isn't all about "looks," now they see the
consequences. I
can longer sit comfortably, I have diabetes, high cholesterol,
neorapathy, and
many other debilitating issues related to surviving where others have
not. I
just hope others can come to grips with their personal journey with
HIV, and
sepport if they need it. Go to a support group or seek out online
forums such as
PozGroup to help cope. Ricky in Michigan



************************************** See what's ne


Need a vacation? Get great deals to amazing places on Yahoo! Travel.

#22976 From: PoWeRTX@...
Date: Sat Sep 29, 2007 9:45 am
Subject: Antihypertensive Treatment May Help Maintain Memory
nelsonvergel
Offline Offline
Send Email Send Email
 
 
 

Publication Logo

Antihypertensive Treatment May Help Maintain Memory


Caroline Cassels
.

September 27, 2007 — New research indicates antihypertensive treatment leads to increased, joint activation of brain areas responsible for memory performance — a finding that suggests such treatment may help patients maintain cognition and memory.

A study led by J. Richard Jennings, PhD, from the University of Pittsburgh, in Pennsylvania, and presented at the American Heart Association (AHA) 61st Annual Fall Conference of the Council for High Blood Pressure Research, showed patients had a 2-fold increase in the joint activation of these areas of the brain after a year of treatment with either the angiotensin-converting enzyme lisinopril or beta blocker atenolol.

While there is an established link between hypertension and mild cognitive deficits, the mechanism has not been clear. Previous research by Dr. Jennings's team used brain imaging to examine the correlation among the activation of the prefrontal areas, parietal areas, and amygdala/hippocampus in hypertensives compared with controls and found it was higher in individuals with high blood pressure.

Increased Correlation

"In the first study, we found that in hypertensive individuals the correlation between levels of activation of these areas of the brain was 0.61. Our next question was, If we successfully treated these individuals [for hypertension], would this finding be reversed and would their brain function look more like normotensives?" Dr. Jennings told Medscape Neurology & Neurosurgery.

"To our surprise, we found that rather than decreasing, the correlation increased to 0.90. Thus, these areas of the brain were nearly always activated at the same level, suggesting there was less specificity, which means that instead of each area doing its own specific job, they were all working at the same time to try to solve the [memory] task," he added.

The study included 28 never-medicated hypertensives, randomized to receive treatment with lisinopril or atenolol for 1 year. All patients underwent psychological and physiological tests, magnetic resonance structural imaging, and positron emission tomography.

Pretreatment correlation of parietal and prefrontal change was 0.61 vs 0.94 after treatment. According to the investigators, similar differences were observed for all areas, with an average pretreatment correlation of 0.66 vs an average posttreatment correlation of 0.91.

Mental Fatigue?

These findings, said Dr. Jennings, suggest hypertensive patients' brains adapt to maintain their intellectual function and that antihypertensive treatment appears to maintain or even augment this adjustment.

At this point, said Dr. Jennings, it is not clear whether there is a "cost" associated with the brain's adaptation to hypertension. "It could mean that [in patients with hypertension] the brain has to work harder, and this could result in mental fatigue, but at this point we just don't know," he said.

This question, he added, will be the focus of future research. In addition, he said, the investigators also want to look at different types of antihypertensive treatments to determine whether they have effects similar to the 2 agents studied in the current work.

According to AHA president Daniel Jones, MD, this study provides reassurance to individuals concerned about potential adverse cognitive effects of antihypertensive treatment. "Treating hypertension is beneficial not only for extending life, but also for improving quality of life," he said in a statement.

The study was funded by the National Heart, Lung, and Blood Institute of the National Institutes of Health.

American Heart Association 61st Annual Fall Conference of the Council for High Blood Pressure Research: Abstract P105. Presented September 27, 2007.



Related Links

 

Regards,

Nelson Vergel
powerusa dot org




See what's new at AOL.com and Make AOL Your Homepage.

#22975 From: "Patrick Flowers" <pf5027@...>
Date: Sat Sep 29, 2007 12:50 pm
Subject: RE:BONES BREAKING
pec-man
Offline Offline
Send Email Send Email
 
It's early morning here in Florida, so please forgive any typos
 
I am sorry to hear about your bone problems, BUT I am having similar problems, and after lots of searching and talking with doctors there are some things you can do to help.
 
This is a guess, but are you on truvavda or viread by any chance?
I never had any problems with my bones until i went on truvavda (which contains viread), norvir and invirase, been one continuous problem after another, unfortunately I don't have any choices left, if you do, switch from truvada or viread to something else
 
Do you smoke, drink a lot of coffee or soda?
Smoking causes poor circulation, which can effect bone big time, I smoke myself and I know quitting is hard
Coffee and Soda have been proven to cause bone problems, it's not only the caffeine but the phosphates in soda can cause weakened bones and osteoporosis at an early age, that added to the meds effects can definitely be a factor
 
Are you on any acid reflux medication?
Acid reflux medications lower the amount of calcium absorbed by the body, calium carbonate requires acid to be digested and absorbed, calcium citrate DOES NOT require stomach acid to be absorbed
On the good side with 2 doses of calcium carbonate a day, I have stopped acid reflux medicines, because the carbonate actually absorbs stomach acid
 
Be sure if you take calcium  to take 2 doses per day with food, taking a large amount at one time, it will pass right through, your body can only absorb so much calcium at one time
And be sure it is a calcium-Vitamin D product, not calcium alone
 
You will most likely be put on boniva or fosomax, to help rebuild the bone, which of course these pills have their own fair share of side effects
 
I have been trying to get my doc to put me back on testosterone, but all I get from her is your "levels are normal". Well testo has a load of GOOD SIDE effects, it not only helps with insulin resistance, it helps strengthen bone, so get that checked too
 
I don't remember if I have ever posted to this group, but I do read all the info and am very thankful to all who post, thanks to that hottie Nelson too
If something comes to mind that i forgot to put in this note, i'll post it
Get those bones strong, stay healthy
Big hug to all
Pat

#22974 From: JuLev@...
Date: Sat Sep 29, 2007 8:04 am
Subject: NATAP: New NNRTI Etravirine (TMC125)
jules72orange
Offline Offline
Send Email Send Email
 
Etravirine is a New NNRTI for NNRTI Resistant HIV
For NNRTI treatment-experienced individuals this new NNRTI is the first that will be effective against HIV resistant to NNRTIs. The FDA is reviewing the manufacturer Tibotec's new drug application now and the expected date for a decision on approval is Jan 18, 2008. This is a very unique time for patients with the newly emerging availability of several new HIV drugs all at once all effective against resistance. this includes the first integrase inhibitor Raltegravir from Merck and the first CCR5 antagonist Maraviroc from Pfizer. Maraviroc was approved last month and is now available in the pharmacy and Raltegravir is expected to be approved this month October. Last year TMC114 also called Darunavir was approved by the FDA. Darunavir is effective for patients with resistance to other protease inhibitors. And of course several years ago the first fusion inhibitor Fuzeon became available. And a few years ago tipranavir a protease inhibitor also effective for patients with resistance to other protease inhibitors became available. Putting all this together this is a unique and very great time for patients with drug resistance who have had trouble putting together an effective regimen. The Intl AIDS Society Treatment Guidelines Committee said this time is so unique that ALL PATIENTS should now have as a goal of therapy achieving <50 copies/ml of HIV viral load. A key point to keep in mind is that if you don't use a potent regimen, one that reduces viral load to under 50 you can get resistance to the integrase inhibitor and lose this potent new class of drugs and get resistance to the other drugs in your regimen including the CCR5 drug Maraviroc.

Efficacy and safety of etravirine (TMC125) in patients with highly ...

Etravirine
is the first NNRTI to show clinical efficacy over 24 weeks, with or without enfuvirtide or a PI, after previous nevirapine or efavirenz failure, ...
www.natap.org/2007/HIV/032807_05.htm




**************************************
See what's new at http://www.aol.com

#22973 From: simon collins <simon.collins@...>
Date: Sat Sep 29, 2007 10:37 am
Subject: Re: Low CD4 Counts
simoninbrixt...
Offline Offline
Send Email Send Email
 
Hi Eric
I've read a few reports about this recently - perhaps 20% of people don't get a raise of 25 cells in the first 6 months.

You could try dropping the nukes and adding saquinavir (Invirase) to Norvir and Reyataz. A small study at the IAS conference a couple of months ago included an interesting small study looking at this:

http://www.i-base.info/htb/v8/htb8-8-9/CD4.html

Simon


I have been on HAART for 2 years now and my viral load is undetectable
but my CD4 counts hover around the 200 mark. I am taking Truvada,
Norvir and Reyataz. My ID Doctor is stumped about this and I was
wondering if anyone could recommend anything to get my CD4s on the rise?

#22972 From: John Barrow <pozbod@...>
Date: Sat Sep 29, 2007 8:11 am
Subject: Re:Kaposi's Sarcoma Seen in Healthy Patients
johnftl59
Offline Offline
Send Email Send Email
 
Kaposi's Sarcoma Seen in Healthy Patients
Doctors in San Francisco recently reported the appearance of Kaposi's sarcoma 
in some HIV infected patients who are taking antiretrovirals and have a 
high CD4 count and low viral load. There is currently no explanation for this 
observation. 

KS is seen in people who don't have HIV.  There have also been identified clusters in "Highly Active" gay men, who were HIV negative.  KS is the result of a viral infection.   It's not that big a surprise that you might see it expressed, even in the absence of HIV.

JB

#22971 From: John Barrow <pozbod@...>
Date: Sat Sep 29, 2007 8:08 am
Subject: Re:Gardasil -- New Video Reveals Hidden Dangers
johnftl59
Offline Offline
Send Email Send Email
 
The spread of this utter crap about Gardasil is the work of weirdos
from the radical Christian right and other morons from "alternative"
medicine, who are just opposed to vaccines.

The deaths and morbidities attributed to gardasil are at best
distortions and most of them are just plain outright lies.

and people wonder why I get upset about the crap masquerading as
"alternative" medicine.


JB

#22970 From: PoWeRTX@...
Date: Sat Sep 29, 2007 1:21 am
Subject: About the termination of Merck's HIV vaccine study, from aidsmap
nelsonvergel
Offline Offline
Send Email Send Email
 

The termination of Merck’s STEP HIV vaccine study last Friday has sent shock waves through the research world. This vaccine was expected to work, based on animal studies and early human studies.

But it didn’t. Not only did it fail to protect against HIV infection, it also failed to moderate viral load levels in people who became infected during the study.

The vaccine was being developed in an ambitious vaccine programme by Merck, which clearly wanted the scientific kudos of being the first to develop an HIV vaccine.

It was designed to stimulate cellular immune responses from CD4 and CD8 cells to HIV proteins contained in the vaccine, in the hope that these would either prevent infection or control viremia if infection took place.

The initial result of the STEP study suggests this approach might not work, and several studies of the Merck vaccine and similar vaccines have been put on hold while the investigators wait for more information.

However the Treatment Action Group warned in a press release last Monday that it would be premature to dismiss vaccines designed to stimulate cell-mediated immunity based on one failure.

They point out that numerous variables may affect the success of T-cell based vaccines, including the proteins contained in the vaccine, the immune system genetics of the participants and the priming and boosting schedule of vaccinations.

Geovax, one company that is also pursuing a T-cell based vaccine, issued a statement explaining why its vaccine is different, including the fact that it uses a different vector (a non-disease causing virus that carries the HIV genes) that is live, and hence can be expected to produce a stronger immune response at the time of vaccination – or greater immune activation, paradoxically increasing the risk of HIV infection.

The results of the STEP study are of particular concern for future recruitment to studies like PAVE, which is due to recruit at least 8,500 people to test a similar type of T-cell based vaccine. Will individuals volunteer for studies of this sort if they gain the perception from the media that all vaccines of this type are flawed?

The findings of the STEP study are disappointing, but as the AIDS Vaccine Advocacy Coalition pointed out this week, “A successful clinical trial is one that produces a scientifically accurate result. It may not be the result you had hoped for, but it answers questions that help the field move forward.”

What’s needed now is prompt and full analysis of the data from the STEP study, so that everyone can learn from this study and move on, rather than alarmist predictions that a vaccine may be out of reach.

Nevertheless, the findings do remind us that research into other prevention strategies continues to be essential. Pre-exposure prophylaxis is one of the avenues that needs investigation; a study published last week calculated that it could prevent up to three million HIV infections over ten years in Africa.

 

Regards,

Nelson Vergel
powerusa dot org




See what's new at AOL.com and Make AOL Your Homepage.

#22969 From: PoWeRTX@...
Date: Sat Sep 29, 2007 1:17 am
Subject: High fat diet accelerates progression of HIV-like virus
nelsonvergel
Offline Offline
Send Email Send Email
 

High fat diet accelerates progression of HIV-like virus

A diet high in saturated fat and cholesterol accelerates disease progression and death in monkeys infected with the simian immunodeficiency virus, say US researchers in the October 15th edition of the Journal of Infectious Diseases.

Read More >>

 

Regards,

Nelson Vergel
powerusa dot org




See what's new at AOL.com and Make AOL Your Homepage.

#22968 From: PoWeRTX@...
Date: Sat Sep 29, 2007 1:19 am
Subject: HIV replication can continue in the intestines even with successful antiretrovir
nelsonvergel
Offline Offline
Send Email Send Email
 

HIV replication can continue in the intestines even with successful antiretroviral therapy

HIV replication continues in intestinal mucosa even if a patient is taking successful antiretroviral therapy, according to a study published in the October edition of AIDS.

Read More >>

 

Regards,

Nelson Vergel
powerusa dot org




See what's new at AOL.com and Make AOL Your Homepage.

#22967 From: Robb DeNyse <robbdenyse@...>
Date: Fri Sep 28, 2007 11:55 pm
Subject: Re: selenium
robbdenyse
Offline Offline
Send Email Send Email
 
Barbara, that's great news about your "numbers" and your continued good health.  But I do have a question:
 
In your message you said "when I went in for my labs, my CD4s were normal and my ratio was 1.2 which amazed my doctor. I always had a decent percentage of CD4s (about 30% or so) but my ratio was always off, like .8 or .9 with my CD8s outnumbering my CD4s."  I know nothing about CD4 ratios and my doctor has never mentioned it.  Is this something I should be concerned about?  I've been undetectable since I've started my meds back in 1998.  Have I been missing something important?
 
Thanks,
Robb in Memphis, TN


Looking for a deal? Find great prices on flights and hotels with Yahoo! FareChase.

#22966 From: PoWeRTX@...
Date: Sat Sep 29, 2007 1:18 am
Subject: Past treatment with amprenavir/fosamprenavir associated with presence of resista
nelsonvergel
Offline Offline
Send Email Send Email
 

Past treatment with amprenavir/fosamprenavir associated with presence of resistance that can reduce susceptibility to darunavir

Resistance mutations reducing susceptibility to the boosted protease inhibitor darunavir (Prezista) are rare in both treatment-naďve and treatment-experienced patients, according to a study published in the October 15th edition of Clinical Infectious Diseases.

Read More >>

 

Regards,

Nelson Vergel
powerusa dot org




See what's new at AOL.com and Make AOL Your Homepage.

#22965 From: Nelson Vergel <nelsonvergel@...>
Date: Sat Sep 29, 2007 1:09 am
Subject: Re: Bones Breaking
nelsonvergel
Offline Offline
Send Email Send Email
 
Several studies have shown that  people with HIV have lower bone density. A
study showed an incidence of osteopenia of 42 %. It seems that it is not caused
by meds but by HIV infection itself, with meds making it worse in some cases.

I would get a full body DEXA scan if I was you two, and get on some
calcium/vitamin D, resistance training, and a bone density drug like Fosamax if
you can. Also get your testosterone and thyroid levels checked.

Regards,
Nelson Vergel
powerusa dot org

----- Original Message ----
From: la1982guy <la1982guy@...>
To: PozHealth@yahoogroups.com
Sent: Friday, September 28, 2007 6:06:30 PM
Subject: [PozHealth] Bones Breaking

My partner and I are 25+ year survivors. Is anyone else out there
having problems with bone density being normal, but ribs and vertabrae
breaking for no apparent reason? My partner's thoracic vertabrae are
compression fracturing for no reason. His neurosurgeon deosn't even
have an explanation.



Welcome to our PozHealth group!

If you received this email from someone who forwarded it to you and would like
to join this group, send a blank email to PozHealth-subscribe@yahoogroups.com
and you will get an email with instructions to follow.

You can chose to receive single emails or a daily digest (collection of emails).
You can post pictures, images, attach files and search by keyword old postings
in the group.

For those of you who are members already and want to switch from single emails
to digest or vice versa, visit www.yahoogroups.com, click on PozHealth, then on
"edit my membership" and go down to your selection. The list administrator does
not process any requests, so this is a do-it-yourself easy process ! :)

Thanks for joining. You will learn and share a lot in this group!

NOTE: I moderate, approve or disapprove emails before they are posted. Please
follow the guidelines shown in the homepage. I will not allow rudeness, sexually
explicit material, attacks, and anyone who does not follow the rules. If you are
not OK with this, please do not join the group.

Forward this email to anyone who may benefit from this information! Thanks!

In Health,

Nelson Vergel (PoWeRTX@...)
List Founder and Moderator

Yahoo! Groups Links

#22964 From: "la1982guy" <la1982guy@...>
Date: Fri Sep 28, 2007 11:06 pm
Subject: Bones Breaking
la1982guy
Offline Offline
Send Email Send Email
 
My partner and I are 25+ year survivors. Is anyone else out there
having problems with bone density being normal, but ribs and vertabrae
breaking for no apparent reason? My partner's thoracic vertabrae are
compression fracturing for no reason. His neurosurgeon deosn't even
have an explanation.

#22963 From: Butch <longjohnmaniac@...>
Date: Fri Sep 28, 2007 7:46 pm
Subject: Re: selenium (toxicity)
longjohnmaniac
Offline Offline
Send Email Send Email
 
The toxic dose for selenium is much higher than is usually thought, according to Dr. Donald Lisk of Cornell University.  Over 2500mcg (that's micrograms = 2.5mg) is toxic.  The recommendations for supplementation are much lower than that.  Dr. Will Taylor, who has investigated selenium deficiciency in HIV suggests up to 800mcg per day for those living with HIV.   Healthy people can benefit by making sure they get at least 200 mcg per day.
Interestingly, Dr. Lisk has investigated selenium content in brazil nuts and other foods.  Brazil nuts are high in selenium so you might think if you ate a lot of brazil nuts you must use caution.  You should, if the nuts are unshelled.  Unshelled brazil nuts contain up to 100 mcg per nut.  However,  nuts which have been shelled and shored unshelled can contain much lower doses - as little as 12-25mcg per nut.   The problem with getting selenium from Brazil nuts is that the content among individual nuts varies greatly.  That's why I prefer to get mine from selenium yeast tablets, very cheap and you know the dose.  Obviously, if you eat a lot of unshelled brazil nuts, you should use caution in supplementation, but most people don't eat that many unshelled brazil nuts.
http://www.cancerdecisions.com/121001.html
or here
http://www.blackwell-synergy.com/doi/abs/10.1111/j.1745-4565.1989.tb00527.x
Selenium
Posted by: "cacrcoastal" cacrcoastal@... cacrcoastal
Date: Thu Sep 27, 2007 2:16 pm ((PDT))

Just a quick note: Selenium could be toxic if taken in large doses,
and I beleive it doesn't take much more to become toxic and potentially

dangerous. That said, we had a HIV neurologist speak at a recent
gathering a few months back and selenium was mentioned I beleive as a
good thing. However, I wouldn't recommend more than 200 mcg per day.

Whether it builds up in the body to become toxic, I don't know. But
my 'gut' feeling is that if you can get those 200mcg in a multi
vitamin, then go for it. But by itself, seems to me like taking a
bunch of Zinc pills. Good for you,but also bad for you. Kinda like
my typing! :-)!



Need a vacation? Get great deals to amazing places on Yahoo! Travel.

#22962 From: rolyatffej@...
Date: Fri Sep 28, 2007 2:24 pm
Subject: Low CD4 counts
rolyatffej
Offline Offline
Send Email Send Email
 
In a message dated 9/28/2007 6:09:23 AM Pacific Standard Time, PozHealth@yahoogroups.com writes:
3. Low CD4 Counts
    Posted by: "Eric" egrid515@... egrid515
    Date: Thu Sep 27, 2007 8:03 am ((PDT))

I have been on HAART for 2 years now and my viral load is undetectable
but my CD4 counts hover around the 200 mark.  I am taking Truvada,
Norvir and Reyataz.  My ID Doctor is stumped about this and I was
wondering if anyone could recommend anything to get my CD4s on the rise?
The ACTG is doing a study of keratinocytic growth factor (it has another name which escapes me at the moment--JB?) for people in just your situation.  Go to their website at http://aactg.org to find a study site near you, to see if they're participating in the trial.
 
Good luck!
Jeff in Palm Springs

 




See what's new at AOL.com and Make AOL Your Homepage.

#22961 From: TheLifeGroupLA@...
Date: Fri Sep 28, 2007 2:11 pm
Subject: November Support Group Facilitator Training!!
thelifegroupla
Offline Offline
Send Email Send Email
 
The Life Group LA is looking for English and Spanish Speaking Support Group Facilitators!!

As our programs grow and the need to serve our community grows even larger, TLGLA is searching for English Speaking, AND Bilingual Spanish Speaking Volunteers!

In 2008 we will be reviving the much needed and popular program, "VIDAS POSITIVA'S", the POZ Life Weekend Seminar done entirely in Spanish!

November Support Group Facilitator Training!!

TLGLA is developing an excellent reputation in the Southern California area for the highest quality of trained volunteers.

We invite and encourage you to become one of them, and become part of our family of compassionate caregivers.

The training requires a commitment of three full days (no exception to this) to receive your certificate of completion, and our next training will be on Saturday and Sunday, November 3rd and 4th and resumes Saturday November 10th in the Los Angeles area.

By attending our training you will enhance your skills in:

" Model of Compassionate Presence
" Active Listening
" Giving and Receiving Constructive Feedback
" Acknowledging and Embracing Diversity
" Cultural Sensitivity
" Crisis Management
" Identifying hidden agendas
" Role Plays
" Recognizing Substance Abuse
" Establishing Rapport
" Non-verbal Communication,
" Setting appropriate Boundaries, and much more!

You may have previously attended one of our POZ Life Weekend Seminars, been at one of our fundraisers or helped out on our Tech Team. If you are ready to give more, or give back to your community, being trained on how to facilitate an emotional support group might be your next experience with us!

Even if you don't have the time to take on the commitment of a regular, weekly support group, our trained facilitators also facilitate the support groups at our POZ Life Weekend Seminars and help in other capacities that occur less frequently, like our fundraising team, outreach team, volunteer development and organizational development!

Think about it! When you decide this may perhaps be the next experience in your volunteer life, email Volunteer@... for an application, or visit our website to download it! (http://thelifegroupla.org/volunteer.html)

Here's a chance to learn or enhance your skills, and share the gifts you have within yourself to give with others!



**************************************
See what's new at http://www.aol.com

#22960 From: Jonathan Goldman <yangzpa@...>
Date: Fri Sep 28, 2007 6:07 pm
Subject: Project Inform's November Volunteer Hotline Operator Training in San Francisco
yangzpa
Offline Offline
Send Email Send Email
 
Starting OCtober 1st, San Francisco-based Project Inform is accepting
on line and telephone inquiries from local S.F. Bay area residents
interested in volunteering for our National HIV/AIDS Treatment
Hotline. The orientation and training will take place at our San
Francisco office, on Thursday evening, November 15 and continue on
Saturday, November 17. Volunteers will be oriented on Project
Inform’s services and our mission- which for over twenty years has
been providing information about the treatment and monitoring of HIV
disease; advocating to facilitate research toward a cure and for
appropriate regulatory policies, legislation and funding for HIV
research, treatment, and care; and, inspiring people living with and
affected by HIV/AIDS to make informed choices, taking effective
action in the fight against HIV, and choosing hope over despair.

Operators speak with callers from the U.S., Canada and elsewhere
answering questions about treatments and assisting with referrals for
finding delivery of health care services and programs. Training
includes PI’s five-part model which frames many of our conversations:

1. Health Maintenance;
2. Supportive Care;
3. Antiretroviral Strategy;
4. Opportunistic Infection Strategy; and
5. Immune Health.

Volunteers should be available for a weekly, three-hour hotline shift
between 10:00 a.m. and 4:00 p.m., Monday to Friday with a six month
commitment.

Jonathan Goldman, the Hotline Manager had been a volunteer operator
for ten years before becoming a full-time staff member in October
2006. PI’s small group of dedicated staff, led by Founding Director,
Martin Delaney is most nurturing of its volunteers.

Richard, a newer operator states, “volunteering on the Hotline with
so much current and correct information available, whether to assist
callers in sorting through the glut of data and circulating reports,
offering the latest treatment developments, or finding a specific
referral, has been very rewarding.”  With the anticipated FDA
approval of a new class of drug, the upcoming majorly-revised Federal
Treatment Guidelines due in late October plus changes to Medicare
Part D, P.I. expects increases in our call volume.

Project Inform encourages inquiries from women, men, transgender,
youth, gay, lesbian, straight, questioning, people of color,
differently-abled persons including HIV and those who are bilingual,
especially with Spanish skills.

Please contact Jonathan Goldman at jgoldman@...;
415-558-8669, x215 or via the Hotline at either 1-866-HIV-INFO or
415-558-9051.

National HIV/AIDS Treatment Hotline
1-866-HIV-INFO (448-4636)




Healthfully & electronically,
      Jonathan "Gravy Boat" Goldman
         Project Inform Hotline Manager
            415.558.8669, x215
         National HIV/AIDS Treatment Hotline 800.822-7422
             jgoldman@... / www.projectinform.org


"Better to remain silent and be thought a fool than to speak out and remove all
doubt."
attributed to Abraham Lincoln

Messages 22960 - 22990 of 31322   Newest  |  < Newer  |  Older >  |  Oldest
Advanced
Add to My Yahoo!      XML What's This?

Copyright © 2009 Yahoo! Inc. All rights reserved.
Privacy Policy - Terms of Service - Guidelines - Help